secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310670
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call
----------------------------------------------------------------------------

- Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.
- Specific efficacy, safety, and biomarker outcomes not available from provided text.
- Conference call hosted by CEO Nello Mainolfi and CMO Jared Gollob.
- KT-621 is first-in-class oral STAT6 degrader targeting Th2-driven inflammation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/0001193125-25-310670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer